No description available.

INTRODUÇÃO: A Síndrome de Rubinstein-Taybi (RTS) é uma doença genética rara, caracterizada por dismorfismos craniofaciais típicos, polegares e háluces alargados, deficiência mental e baixa estatura. A incidência estimada é de 1: 125 000 a 1: 330000 nativivos. A SRT geralmente ocorre esporadicamente, mas pode ser herdada com um padrão de herança autossômico dominante. O diagnóstico da SRT é essencialmente clínico. OBJETIVOS: Realizar o estudo genético-clínico e citogenético em 30 pacientes brasileiros com SRT, e descrever de forma sistematizada a freqüência de dismorfismos faciais e malformações múltiplas encontradas. MÉTODOS: Neste estudo observacional retrospectivo e prospectivo, os pacientes foram seguidos no período de agosto de 2005 a junho de 2009. O cariótipo com bandeamento G foi realizado em todos os pacientes. RESULTADOS: A maioria dos pacientes avaliados foi do sexo feminino (60%). As seguintes características foram observadas em todos os pacientes da nossa casuística: atraso de desenvolvimento neuropsicomotor, ponta nasal voltada para baixo, columela proeminente, sorriso característico, dificuldades alimentares na infância, persistência dos coxins fetais, falanges distais dos polegares alargadas e pés planos. A baixa estatura e a microcefalia foi observada em 80% e 76% dos casos, respectivamente. As principais características craniofaciais observadas foram: fronte proeminente (86%), ponte nasal larga (60%), hipertelorismo (70%), sobrancelhas espessas e arqueadas (96%) cílios longos em 93%, prega epicântica (76%), fissura palpebral infra vertidas (76%), abertura bucal estreita (93%), retrognatismo (76 %), sorriso característico em 100%, palato alto e estreito (93%), anomalias dentárias (83%). Outras anomalias identificadas foram: estrabismo, erros de refração, obstrução do canal lacrimal, háluces e polegares alargados, angulação de polegares, anomalias do pavilhão auricular (rotação/posição/tamanho/forma), angulação do hálux, clinodactilia, sobreposição dos pododáctilos, falanges distais alargadas de outros dedos, marcha rígida, hipotonia, sopro cardíaco, cardiopatia congênita, criptoquidia, hemangioma plano e hipertricose. Uma paciente apresentou translocação recíproca de novo 46, XX, t (2; 16)(q36.3; p13.3). CONCLUSÕES: A raridade da SRT e o amplo espectro das manifestações clínicas pode atrasar o diagnóstico clínico. A média da idade ao diagnóstico dos nossos pacientes com SRT foi de três anos e oito meses. Todas as crianças devem receber avaliação por geneticista pediátrico, cardiologista, oftalmologista, neuropediatra, e odontopediatra / INTRODUCTION: Rubinstein-Taybi syndrome (RTS) is a rare genetic disorder characterized by distinctive craniofacial dysmorphisms, broad thumbs and toes and mental and statural deficiency. The prevalence of RTS has been estimated to be 1 in 125000 to 1: 330000 live births. RTS usually occurs sporadically although it can be inherited as an autosomal dominant disorder. The diagnosis of RTS is primarily based on clinical features. OBJECTIVES: We performed a clinical and cytogenetic assay in a group of 30 Brazilian RTS patients. We also decribed the frequencies of facial dysmorphisms and multiple malformations. METHODS: In this observational retrospective and prospective study, the patients were followed from August 2005 to June 2009. Chromosomal analysis was performed by G-banding karyotype. RESULTS: Most of the patients were female (60%).The following abnormalities were present in all of the patients: delayed psychomotor development, beaked nose, proeminent collumel, typical facies, broad thumbs and toes, flat feet, joint laxity, feeding problems during the childhood, and finger pads. Short stature was present in 80%, and microcephalia in 76% of the cases, respectively. Main craniofacial characteristics are frontal bossing (86%), wide nasal bridge (60%), ocular hyperthelorism (70%), high arched eyebrows (96%), long eyelashes (93%), epicathal folds (76%), downslanting palpebral fissures (76%), small opening of the mouth (93%), retrognathism (76%), grimacing smile (100%), high arched palate (93%), and dental anomalies (83%). Other findings were: strabism, refractive error, lacrimal obstruction, wide thumb and halux, angulated thumbs, external ears anomalies (rotation, implantation and morfology), angulated halux, clinodactyly, crowded toes, broad distal falanges of other fingers, stiff gait, hipotonia, cardiac murmur, congenital heart defect, undescendent testis, hypertrichosis, and hemangioma. One female patient has found to have a reciprocal de novo translocation t(2;16)(q36.3;p13.3) on G-banding karyotype CONCLUSIONS: The rarity of RTS and the wide spectrum of clinical manifestations, may delay the clinical diagnosis of RTS. The average age at the diagnosis of our patients was 3 years and 8 months. All children of RTS should receive an evaluation by a pediatric geneticist, cardiologist, ophthalmologist, pediatric neurologist, and pediatric dentist

INTRODUÇÃO: A Síndrome de Rubinstein-Taybi (RTS) é uma doença genética rara, caracterizada por dismorfismos craniofaciais típicos, polegares e háluces alargados, deficiência mental e baixa estatura. A incidência estimada é de 1: 125 000 a 1: 330000 nativivos. A SRT geralmente ocorre esporadicamente, mas pode ser herdada com um padrão de herança autossômico dominante. O diagnóstico da SRT é essencialmente clínico. OBJETIVOS: Realizar o estudo genético-clínico e citogenético em 30 pacientes brasileiros com SRT, e descrever de forma sistematizada a freqüência de dismorfismos faciais e malformações múltiplas encontradas. MÉTODOS: Neste estudo observacional retrospectivo e prospectivo, os pacientes foram seguidos no período de agosto de 2005 a junho de 2009. O cariótipo com bandeamento G foi realizado em todos os pacientes. RESULTADOS: A maioria dos pacientes avaliados foi do sexo feminino (60%). As seguintes características foram observadas em todos os pacientes da nossa casuística: atraso de desenvolvimento neuropsicomotor, ponta nasal voltada para baixo, columela proeminente, sorriso característico, dificuldades alimentares na infância, persistência dos coxins fetais, falanges distais dos polegares alargadas e pés planos. A baixa estatura e a microcefalia foi observada em 80% e 76% dos casos, respectivamente. As principais características craniofaciais observadas foram: fronte proeminente (86%), ponte nasal larga (60%), hipertelorismo (70%), sobrancelhas espessas e arqueadas (96%) cílios longos em 93%, prega epicântica (76%), fissura palpebral infra vertidas (76%), abertura bucal estreita (93%), retrognatismo (76 %), sorriso característico em 100%, palato alto e estreito (93%), anomalias dentárias (83%). Outras anomalias identificadas foram: estrabismo, erros de refração, obstrução do canal lacrimal, háluces e polegares alargados, angulação de polegares, anomalias do pavilhão auricular (rotação/posição/tamanho/forma), angulação do hálux, clinodactilia, sobreposição dos pododáctilos, falanges distais alargadas de outros dedos, marcha rígida, hipotonia, sopro cardíaco, cardiopatia congênita, criptoquidia, hemangioma plano e hipertricose. Uma paciente apresentou translocação recíproca de novo 46, XX, t (2; 16)(q36.3; p13.3). CONCLUSÕES: A raridade da SRT e o amplo espectro das manifestações clínicas pode atrasar o diagnóstico clínico. A média da idade ao diagnóstico dos nossos pacientes com SRT foi de três anos e oito meses. Todas as crianças devem receber avaliação por geneticista pediátrico, cardiologista, oftalmologista, neuropediatra, e odontopediatra / INTRODUCTION: Rubinstein-Taybi syndrome (RTS) is a rare genetic disorder characterized by distinctive craniofacial dysmorphisms, broad thumbs and toes and mental and statural deficiency. The prevalence of RTS has been estimated to be 1 in 125000 to 1: 330000 live births. RTS usually occurs sporadically although it can be inherited as an autosomal dominant disorder. The diagnosis of RTS is primarily based on clinical features. OBJECTIVES: We performed a clinical and cytogenetic assay in a group of 30 Brazilian RTS patients. We also decribed the frequencies of facial dysmorphisms and multiple malformations. METHODS: In this observational retrospective and prospective study, the patients were followed from August 2005 to June 2009. Chromosomal analysis was performed by G-banding karyotype. RESULTS: Most of the patients were female (60%).The following abnormalities were present in all of the patients: delayed psychomotor development, beaked nose, proeminent collumel, typical facies, broad thumbs and toes, flat feet, joint laxity, feeding problems during the childhood, and finger pads. Short stature was present in 80%, and microcephalia in 76% of the cases, respectively. Main craniofacial characteristics are frontal bossing (86%), wide nasal bridge (60%), ocular hyperthelorism (70%), high arched eyebrows (96%), long eyelashes (93%), epicathal folds (76%), downslanting palpebral fissures (76%), small opening of the mouth (93%), retrognathism (76%), grimacing smile (100%), high arched palate (93%), and dental anomalies (83%). Other findings were: strabism, refractive error, lacrimal obstruction, wide thumb and halux, angulated thumbs, external ears anomalies (rotation, implantation and morfology), angulated halux, clinodactyly, crowded toes, broad distal falanges of other fingers, stiff gait, hipotonia, cardiac murmur, congenital heart defect, undescendent testis, hypertrichosis, and hemangioma. One female patient has found to have a reciprocal de novo translocation t(2;16)(q36.3;p13.3) on G-banding karyotype CONCLUSIONS: The rarity of RTS and the wide spectrum of clinical manifestations, may delay the clinical diagnosis of RTS. The average age at the diagnosis of our patients was 3 years and 8 months. All children of RTS should receive an evaluation by a pediatric geneticist, cardiologist, ophthalmologist, pediatric neurologist, and pediatric dentist

In this work, I will describe a new statistical tool: the canonical bicoherence, which is a combination of the canonical coherence and the bicoherence. I will provide its definitions, properties, estimation by multitaper methods and statistics, and estimate the variance of the estimates by the weighted jackknife method. I will discuss its applicability and usefulness in nonlinear quadratic phase coupling detection and analysis for multivariate random processes. Furthermore, I will develop the time-varying canonical bicoherence for the nonlinear analysis of non-stationary random processes. In this thesis, the canonical bicoherence is mainly applied in two types of data: a) three-component geomagnetic field data, and b) high-dimensional brain electroencephalogram data. Both results obtained will be linked with physical or physiological interpretations. In particular, this thesis is the first work where the novel method of ``canonical bicoherence'' is introduced and applied to the nonlinear quadratic phase coupling detection and analysis for multivariate random processes. / Thesis (Ph.D, Mathematics & Statistics) -- Queen's University, 2008-10-31 15:03:57.596

>Magister Scientiae - MSc / Saccharomyces cerevisiae is an important host in industrial biotechnology. This yeast is the host of choice for the first and second-generation biofuels for ethanol production. Genome modification in S. cerevisiae has been extremely successful largely due to this yeast’s highly efficient homology-directed DNA repair machinery. The advent of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing technology has made multi-gene editing in yeast more accessible. In this study, we aimed at targeting the Cas9 to multiple genomic positions for integrating multiple genes at different sites. We have developed two CRISPR-Cas9 systems, based on published one- and two-plasmid systems, for application in S. cerevisiae strains. In this study, these CRISPR-Cas9 systems were used to transform fungal heterologous genes into yeast using the electroporation transformation method. We first utilized the CRISPR systems for targeting the T.r.eg2 gene to single locus chromosomal sites for single copy integration. Subsequently, we then targeted the same gene to repeated sequences in the genome, namely the delta sites, for multi-copy integration. The procedure was repeated with a different gene, T.e.cbh1, integrated into the same sites to ascertain reporter gene specific effects. High integration efficiency was achieved, since all the strains successfully integrated the genes. However, we discovered significant differences in enzyme activities between the two genes when targeted to different loci, as well as varying copy numbers as determined by qPCR. The T.e.cbh1 gene was highly expressed by yeast transformants targeted at the repeated delta sequences used for multi-copy integration, reaching maximum levels of 248 mU/gDCW. The T.r.eg2 gene was highly expressed in yeast transformants targeted to the single locus site on chromosome 12, reaching a maximum of 160U/gDCW, though it was shown that off-target integration likely occurred. We then used the information from these observations to construct a CBP yeast strain containing three cellulase genes: T.r.eg2, T.e.cbh1, and S.f.BGL1. Significant differences in enzyme activities were observed between the three genes, and it was shown that the S.f.BGL1 gene was poorly expressed by the CBP yeast strain, whereas the T.r.eg2 gene was highly expressed. Notably, due to the fact that marker containing plasmids could be cured from these strains, many additional genetic changes can still be made. Overall, our two CRISPR-Cas9 systems were efficient at engineering strains that produce recombinant proteins and can be used in future studies for a variety of applications, including metabolic engineering in S. cerevisiae

La génération des cellules hématopoïétiques, aussi connue sous le nom d'hématopoïèse, est contrôlée par l’activité conjuguée de facteurs de transcription lignée-spécifiques permettant l’expression, en temps et lieu, de gènes spécifiques nécessaires pour le développement cellulaire. Dans le cadre de notre étude, nous avons étudié les facteurs de transcription KLF2 et KLF4 qui jouent des rôles cruciaux dans la formation des lymphocytes B et T. KLF2 et KLF4 activent la transcription de gènes spécifiques via leur interaction avec le co-activateur (CBP). Leurs interactions avec CBP requièrent le domaine de transactivation (TAD) qui est localisé dans la région N-terminal des facteurs KLF2 et KLF4. Des études préalables ont montré que des domaines TAD sont aussi présents chez la protéine suppresseur de tumeur p53 et que ces domaines sont requis pour les interactions entre la protéine p53 et le co-activateur CBP. Récemment, plusieurs structures des TADs de p53 en complexe avec les domaines TAZ2 et KIX de CBP ont permis de démontrer que ces TADs sont de nature acide et contiennent un motif ΦΧΧΦΦ crucial pour la formation des interactions. De plus, il s’avère que ces TADs sont similaires aux TADs de KLF2 et KLF4. L’étude présentée dans ce mémoire relate la caractérisation structurelle et fonctionnelle des interactions formées par les facteurs de transcription KLF2 et KLF4 avec leur partenaire d'interaction, CBP, pour activer la transcription de gènes spécifiques. Nos analyses ont été faites en utilisant différentes techniques telles que le titrage calorimétrique isotherme (ITC), la résonance magnétique nucléaire (RMN) ainsi que des expériences de transactivation chez la levure. Notre étude permet une meilleure compréhension des rôles opposés mais complémentaires qu'ont les protéines KLF2 et KLF4 au cours du développement et de la différentiation des lymphocytes B et T en plus de fournir les détails mécanistiques à la base de leurs interactions. Ces informations seront potentiellement utiles pour le développement d'outils à des fins thérapeutiques dans le cadre des leucémies, notamment. / Hematopoietic development is regulated through a combinatorial interplay between lineage-specific activators and the general transcription factors that enables cell-specific patterns of gene expression. In this study, the transcription factors KLF2 and KLF4 play crucial roles in lymphocytes B and T development by activating transcription of specific genes through interactions with the co-activator (CBP). These interactions involve the transactivation domains (TAD) localized in the N-terminal region of KLF2 and KLF4 factors. Previous studies have shown that TADs are also found in the tumor suppressor protein p53 and these TADs are responsible for the interactions between the p53 protein and the coactivator CBP. Recently, several structures of p53TADs in complex with the TAZ2 and KIX domains of CBP have shown that these TADs are acidic and possess a ΦΧΧΦΦ motif crucial for the formation of the interaction. Interestingly, these TADs are similar to the ones found on KLF2 and KLF4. This thesis provides a structural and functional characterization of the interactions formed by the transcription factors KLF2 and KLF4, which have opposing roles, and competes for the same interacting partner CBP to activate transcription. The analysis is done using isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR) spectroscopy and a yeast activation assay. This study brings a greater understanding on the opposing roles yet complementary of KLF2 and KLF4 proteins involved in B and T lymphocytes specific lineages selection and also provides information for potential therapeutic research regarding disease such as leukemia.

La signalisation par l’estrogène a longtemps été considérée comme jouant un rôle critique dans le développement et la progression des cancers hormono-dépendants tel que le cancer du sein. Deux tiers des cancers du sein expriment le récepteur des estrogènes (ER) qui constitue un élément indiscutable dans cette pathologie. L’acquisition d’une résistance endocrinienne est cependant un obstacle majeur au traitement de cette forme de cancer. L’émergence de cancers hormono-indépendants peut est produite par l’activation de ER en absence d’estrogène, l’hypersensibilité du récepteur aux faibles concentrations plasmique d’estrogène ainsi que l’activation de ER par des modulateurs sélectifs. L’activité du ER est fortement influencée par l’environnement cellulaire tel que l’activation de voie de signalisation des facteurs de croissances, la disponibilité de protéines co-régulatrices et des séquences promotrices ciblées. Présentement, les études ont principalement considérées le rôle de ERα, cependant avec la découverte de ERβ, notre compréhension de la diversité des mécanismes potentiels impliquant des réponses ER-dépendantes s’est améliorée. L’activation des voies des kinases par les facteurs de croissance entraîne le développement d’un phénotype tumoral résistant aux traitements actuels. Nos connaissances des voies impliquées dans l’activation de ER sont restreintes. ERα est considéré comme le sous-type dominant et corrèle avec la plupart des facteurs de pronostic dans le cancer du sein. Le rôle de ERβ reste imprécis. Les résultats présentés dans cette thèse ont pour objectif de mieux comprendre l’implication de ERβ dans la prolifération cellulaire par l’étude du comportement de ERβ et ERα suite à l’activation des voies de signalisation par les facteurs de croissance. Nous démontrons que l’activation des récepteurs de surfaces de la famille ErbB, spécifiquement ErbB2/ErbB3, inhibe l’activité transcriptionnelle de ERβ, malgré la présence du coactivateur CBP, tout en activant ERα. De plus, l’inhibition de ERβ est attribuée à un résidu sérine (Ser-255) situé dans la région charnière, absente dans ERα. Des études supplémentaires de ErbB2/ErbB3 ont révélé qu’ils activent la voie PI3K/Akt ciblant à son tour la Ser-255. En effet, cette phosphorylation de ERβ par PI3K/Akt induit une augmentation de l’ubiquitination du récepteur qui promeut sa dégradation par le système ubiquitine-protéasome. Cette dégradation est spécifique pour ERβ. De façon intéressante, la dégradation par le protéasome requiert la présence du coactivateur CBP normalement requis pour l’activité transcriptionnelle des récepteurs nucléaires. Malgré le fait que l’activation de la voie PI3K/Akt corrèle avec une diminution de l’expression des gènes sous le contrôle de ERβ, on observe une augmentation de la prolifération des cellules cancéreuses. L’inhibition de la dégradation de ERβ réduit cette prolifération excessive causée par le traitement avec Hrgβ1, un ligand de ErbB3. Un nombre croissant d’évidences indique que les voies de signalisations des facteurs de croissance peuvent sélectivement réguler l’activité transcriptionnelle de sous-types de ER. De plus, le ratio ERα/ERβ dans les cancers du sein devient un outil de diagnostique populaire afin de déterminer la sévérité d’une tumeur. En conclusion, la caractérisation moléculaire du couplage entre la signalisation des facteurs de croissance et la fonction des ERs permettra le développement de nouveaux traitements afin de limiter l’apparition de cellules tumorales résistantes aux thérapies endocriniennes actuelles. / It has long been appreciated that estrogenic signaling plays a critical role in the development of hormone-dependent cancers such as breast cancer. Two-thirds of breast cancers express estrogen receptor (ER) which has been demonstrated to play an irrefutable role in tumour development and progression. However the acquisition of endocrine resistance has become a major obstacle in the treatment of hormone-dependent cancers that have acquired a hormone-independent state. Hormone-independent cancers emerge from an array of pathways involving ER activation in the absence of estrogen, hypersensitivity of ER to low serum levels of estrogen and activation by estrogen antagonists. The activity of ER is critically influenced by the cellular environment such as growth factor signaling pathways, availability of coregulatory proteins and the promoter sequence of target genes. The mechanisms studied have mostly considered the role of ERα, however with the discovery of the second subtype, ERβ, the understanding on the diversity of potential mechanisms involving ER-dependent responses have improved. Hormonal-independent activation of ER can occur in estrogen-dependent breast tumours, with concomitant rise in kinase signaling pathways, resulting in the acquisition of a therapeutic resistant phenotype in treated women. Our knowledge is relatively limited on which pathways trigger ER signaling and how these phosphorylation-coupled events affect ER activity. ERα is considered the dominant subtype and correlates with most of the prognostic factors in breast cancers. Conversely the role of ERβ remains unclear. The results presented in this thesis were carried out with the objective of gaining a better understanding of ERβ’s role in cellular proliferation by examining the behavior of ERβ and ERα during the activation of growth factor signaling pathways by cell-surface receptor-tyrosine kinases. We demonstrate here that the activation of cell surface receptors of the ErbB family, specifically ErbB2/ErbB3, inhibits the transcriptional activity of ERβ despite the presence of the coactivator CBP, yet activated ERα. Furthermore the inhibition of ERβ was attributed to a specific serine residue located within the hinge region, not present in ERα. Additional studies of ErbB2/ErbB3-initiated signaling revealed that it triggered the activation of the PI3K/Akt pathway which targeted the serine residue within the hinge region of ERβ. In fact, phosphorylation of ERβ by the PI3K/Akt pathway led to an increase in receptor ubiquitination which promoted its degradation by the ubiquitin-proteasome system which was subtype specific. Interestingly, proteasomal degradation required the presence of the coactivator CBP, which is normally involved in assisting nuclear receptor transcriptional activity. Although the activation of the PI3K/Akt pathway correlated with a decrease in the expression of ERβ target genes it led to an increase in the proliferation of breast cancer cells. Inhibiting the degradation of ERβ reduced the enhanced proliferation of breast cancer cells brought about by the treatment of ErbB3’s ligand, Hrgβ1. Increasing evidence indicates that growth factor signaling pathways can selectively regulate the transcriptional activity of ER subtypes, and the ratio of ERα/ERβ expression in breast tumours is becoming a popular prognostic factor to evaluate the severity of the tumour. Therefore the molecular characterization of the coupling between growth factor signaling and ER function should provide improved therapeutical approaches to overcome or delay the onset of resistance to endocrine therapy in hormone-dependent cancers.

La signalisation par l’estrogène a longtemps été considérée comme jouant un rôle critique dans le développement et la progression des cancers hormono-dépendants tel que le cancer du sein. Deux tiers des cancers du sein expriment le récepteur des estrogènes (ER) qui constitue un élément indiscutable dans cette pathologie. L’acquisition d’une résistance endocrinienne est cependant un obstacle majeur au traitement de cette forme de cancer. L’émergence de cancers hormono-indépendants peut est produite par l’activation de ER en absence d’estrogène, l’hypersensibilité du récepteur aux faibles concentrations plasmique d’estrogène ainsi que l’activation de ER par des modulateurs sélectifs. L’activité du ER est fortement influencée par l’environnement cellulaire tel que l’activation de voie de signalisation des facteurs de croissances, la disponibilité de protéines co-régulatrices et des séquences promotrices ciblées. Présentement, les études ont principalement considérées le rôle de ERα, cependant avec la découverte de ERβ, notre compréhension de la diversité des mécanismes potentiels impliquant des réponses ER-dépendantes s’est améliorée. L’activation des voies des kinases par les facteurs de croissance entraîne le développement d’un phénotype tumoral résistant aux traitements actuels. Nos connaissances des voies impliquées dans l’activation de ER sont restreintes. ERα est considéré comme le sous-type dominant et corrèle avec la plupart des facteurs de pronostic dans le cancer du sein. Le rôle de ERβ reste imprécis. Les résultats présentés dans cette thèse ont pour objectif de mieux comprendre l’implication de ERβ dans la prolifération cellulaire par l’étude du comportement de ERβ et ERα suite à l’activation des voies de signalisation par les facteurs de croissance. Nous démontrons que l’activation des récepteurs de surfaces de la famille ErbB, spécifiquement ErbB2/ErbB3, inhibe l’activité transcriptionnelle de ERβ, malgré la présence du coactivateur CBP, tout en activant ERα. De plus, l’inhibition de ERβ est attribuée à un résidu sérine (Ser-255) situé dans la région charnière, absente dans ERα. Des études supplémentaires de ErbB2/ErbB3 ont révélé qu’ils activent la voie PI3K/Akt ciblant à son tour la Ser-255. En effet, cette phosphorylation de ERβ par PI3K/Akt induit une augmentation de l’ubiquitination du récepteur qui promeut sa dégradation par le système ubiquitine-protéasome. Cette dégradation est spécifique pour ERβ. De façon intéressante, la dégradation par le protéasome requiert la présence du coactivateur CBP normalement requis pour l’activité transcriptionnelle des récepteurs nucléaires. Malgré le fait que l’activation de la voie PI3K/Akt corrèle avec une diminution de l’expression des gènes sous le contrôle de ERβ, on observe une augmentation de la prolifération des cellules cancéreuses. L’inhibition de la dégradation de ERβ réduit cette prolifération excessive causée par le traitement avec Hrgβ1, un ligand de ErbB3. Un nombre croissant d’évidences indique que les voies de signalisations des facteurs de croissance peuvent sélectivement réguler l’activité transcriptionnelle de sous-types de ER. De plus, le ratio ERα/ERβ dans les cancers du sein devient un outil de diagnostique populaire afin de déterminer la sévérité d’une tumeur. En conclusion, la caractérisation moléculaire du couplage entre la signalisation des facteurs de croissance et la fonction des ERs permettra le développement de nouveaux traitements afin de limiter l’apparition de cellules tumorales résistantes aux thérapies endocriniennes actuelles. / It has long been appreciated that estrogenic signaling plays a critical role in the development of hormone-dependent cancers such as breast cancer. Two-thirds of breast cancers express estrogen receptor (ER) which has been demonstrated to play an irrefutable role in tumour development and progression. However the acquisition of endocrine resistance has become a major obstacle in the treatment of hormone-dependent cancers that have acquired a hormone-independent state. Hormone-independent cancers emerge from an array of pathways involving ER activation in the absence of estrogen, hypersensitivity of ER to low serum levels of estrogen and activation by estrogen antagonists. The activity of ER is critically influenced by the cellular environment such as growth factor signaling pathways, availability of coregulatory proteins and the promoter sequence of target genes. The mechanisms studied have mostly considered the role of ERα, however with the discovery of the second subtype, ERβ, the understanding on the diversity of potential mechanisms involving ER-dependent responses have improved. Hormonal-independent activation of ER can occur in estrogen-dependent breast tumours, with concomitant rise in kinase signaling pathways, resulting in the acquisition of a therapeutic resistant phenotype in treated women. Our knowledge is relatively limited on which pathways trigger ER signaling and how these phosphorylation-coupled events affect ER activity. ERα is considered the dominant subtype and correlates with most of the prognostic factors in breast cancers. Conversely the role of ERβ remains unclear. The results presented in this thesis were carried out with the objective of gaining a better understanding of ERβ’s role in cellular proliferation by examining the behavior of ERβ and ERα during the activation of growth factor signaling pathways by cell-surface receptor-tyrosine kinases. We demonstrate here that the activation of cell surface receptors of the ErbB family, specifically ErbB2/ErbB3, inhibits the transcriptional activity of ERβ despite the presence of the coactivator CBP, yet activated ERα. Furthermore the inhibition of ERβ was attributed to a specific serine residue located within the hinge region, not present in ERα. Additional studies of ErbB2/ErbB3-initiated signaling revealed that it triggered the activation of the PI3K/Akt pathway which targeted the serine residue within the hinge region of ERβ. In fact, phosphorylation of ERβ by the PI3K/Akt pathway led to an increase in receptor ubiquitination which promoted its degradation by the ubiquitin-proteasome system which was subtype specific. Interestingly, proteasomal degradation required the presence of the coactivator CBP, which is normally involved in assisting nuclear receptor transcriptional activity. Although the activation of the PI3K/Akt pathway correlated with a decrease in the expression of ERβ target genes it led to an increase in the proliferation of breast cancer cells. Inhibiting the degradation of ERβ reduced the enhanced proliferation of breast cancer cells brought about by the treatment of ErbB3’s ligand, Hrgβ1. Increasing evidence indicates that growth factor signaling pathways can selectively regulate the transcriptional activity of ER subtypes, and the ratio of ERα/ERβ expression in breast tumours is becoming a popular prognostic factor to evaluate the severity of the tumour. Therefore the molecular characterization of the coupling between growth factor signaling and ER function should provide improved therapeutical approaches to overcome or delay the onset of resistance to endocrine therapy in hormone-dependent cancers.

Ο καρκίνος της ουροδόχου κύστης είναι η τέταρτη συχνότερη κακοήθεια στους άνδρες και η δέκατη στις γυναίκες και η ετήσια επίπτωσή του αυξάνει συνεχώς στις ανεπτυγμένες χώρες. Oι προγνωστικοί παράγοντες που χρησιμοποιούνται σήμερα δεν μπορούν να προβλέψουν με βεβαιότητα την μακροπρόθεσμη έκβαση του ουροθηλιακού καρκίνου και έτσι προκύπτει η ανάγκη αναγνώρισης δεικτών με δυνατότητα πρόγνωσης της συμπεριφοράς των καρκινωμάτων. Επιπλέον, δεδομένων των περιορισμένων δυνατοτήτων των σημερινών θεραπευτικών επιλογών (χειρουργική αντιμετώπιση, χημειοθεραπεία ή ανοσοθεραπεία και ακτινοθεραπεία), απαιτούνται νέες θεραπευτικές στρατηγικές. Μία τέτοια στρατηγική είναι η στόχευση σε μεταγραφικούς παράγοντες όπως οι πυρηνικοί υποδοχείς και οι upstream ενεργοποιητές τους. Η διαταραχή αυτών των μεταγραφικών παραγόντων είναι κομβικό σημείο της έναρξης και διατήρησης του κακοήθους φαινοτύπου. O πυρηνικός υποδοχέας PPARγ εμπλέκεται στον έλεγχο του μεταβολισμού, την κυτταρική ανάπτυξη, την αγγειογένεση και την ανοσολογική και φλεγμονώδη απάντηση. Επιπρόσθετα, υπάρχουν ενδείξεις ότι ρυθμίζει τους μηχανισμούς καταστολής αλλά και προαγωγής της καρκινογένεσης. Ο RXRα είναι επίσης μέλος της υπεροικογένειας των πυρηνικών υποδοχέων και ετεροδιμερίζεται με τον PPARγ προς σχηματισμό του συμπλόκου που αλληλεπιδρά με το DNA. Οι προσδέτες των RXR υποδοχέων έχουν ήδη χρησιμοποιηθεί στη χημειοπρόληψη διαφόρων μορφών καρκίνου. Ο μεταγραφικός παράγoντας AP-1, απαρτίζεται από διμερή των Fos και Jun πρωτεϊνών και η δράση του σχετίζεται με την πρόοδο της καρκινογένεσης. Υπάρχουν πάντως και ενδείξεις για προ-αποπτωτική δράση του. Η CBP είναι ένας απ’ τους σημαντικότερους ολοκληρωτές σημάτων της μεταγραφής. Ο ανταγωνισμός μεταξύ των PPARγ και AP-1 για τη CBP είναι ένας απ’ τους μηχανισμούς που εξηγούν την αρνητική «συνομιλία» (cross-talk) μεταξύ των PPARγ και AP-1. Στην παρούσα μελέτη εξετάσαμε τόσο ξεχωριστά όσο και σε συνδυασμό μεταξύ τους, την έκφραση των πέντε μοριακών παραγόντων (PPARγ, RXRα, p-c-Jun, c-Fos, CBP) στο φυσιολογικό ουροθήλιο, τις προκαρκινικές αλλοιώσεις και τα ουροθηλιακά καρκινώματα (ΟΚ). Τα ιστικά δείγματα προήλθαν από 88 ασθενείς οι οποίοι υπέστησαν διαγνωστική βιοψία ή θεραπευτική κυστεκτομή, νεφρεκτομή ή ουρητηρεκτομή. Εφαρμόστηκε η ανοσοϊστοχημική μέθοδος σε τομές παραφίνης και εκτιμήθηκε η σχετική έκφραση των μελετώμενων παραγόντων στα ενδοκυττάρια διαμερίσματα, τις ενδοεπιθηλιακές στιβάδες και τις φυσιολογικές ή παθολογικές ιστολογικές βαθμίδες. Όλοι οι παράγοντες παρουσίασαν κυρίως πυρηνική εντόπιση. Η έκφραση του p-c-Jun ελαττώνεται στους ασθενείς άνω των 70 ετών σε σχέση με τους νεώτερους, ενώ κανένα άλλο απ’ τα μελετώμενα μόρια δε φαίνεται να επηρεάζεται από την ηλικία. Η έκφραση των PPARγ, CBP, p-c-Jun και c-Fos σημειώνει αύξηση κατά την πορεία προς τον καρκίνο. Όσο αφορά στα ΟΚ, οι PPARγ και CBP παρουσιάζουν αρνητική συσχέτιση με την αποδιαφοροποίηση. Επιπλέον ο PPARγ συσχετίζεται αρνητικά με την απόκτηση χαρακτήρων διήθησης στα ΟΚ. Αντιθέτως, η έκφραση του RXRα δεν διακυμαίνεται στατιστικώς σημαντικά σε όλη την πορεία της καρκινογένεσης. Η ανάλυση της συνδυασμένης έκφρασης των πέντε παραγόντων έγινε με σκοπό την αποκάλυψη ενδεχόμενων αλληλεπιδράσεων μεταξύ τους. Η προστατευτική δράση του PPARγ στο ουροθήλιο συνοδεύεται από ταυτόχρονη μέτρια ή ισχυρή έκφραση των RXRα, p-c-Jun και c-Fos. Αναλυτικά, η αυξανόμενη έκφραση του p-c-Jun συμπίπτει με ενίσχυση της θετικής συσχέτισης του PPARγ με καλύτερα διαφοροποιημένους, λιγότερο διηθητικούς όγκους, ενώ ο c-Fos φαίνεται να εξασθενίζει ήπια την ευνοϊκή δράση του PPARγ στη διαφοροποίηση του ουροθηλίου. Η αυξανόμενη έκφραση της CBP έδειξε να εξασθενίζει και τελικά να εκμηδενίζει τη στατιστικά σημαντική αύξηση του PPARγ στην πορεία προς τον καρκίνο και την επαγωγή του στους μη διηθητικούς όγκους σε σύγκριση με τους διηθητικούς. Ταυτόχρονα, η αρνητική σχέση της CBP με την αποδιαφοροποίηση και την αύξηση της κακοήθειας των ΟΚ επηρεάζεται από την παρουσία των PPARγ και AP-1, επιβεβαιώνοντας την υπόθεση της συνομιλίας αυτών των μοριακών παραγόντων. Ενδιαφέρουσα είναι η παρατήρηση ότι οι περισσότερες από τις αναφερθείσες πιο πάνω συσχτίσεις μεταξύ των μοριακών παραγόντων ίσχυαν για μεγαλύτερους των 70 ετών αλλά όχι πάντα για τους νεώτερους ασθενείς. Τα αποτελέσματα της παρούσας μελέτης μπορούν πιθανόν να οδηγήσουν σε συμπεράσματα με εφαρμογή σε χημειοπροληπτικές και θεραπευτικές στρατηγικές για τον ουροθηλιακό καρκίνο. / Bladder cancer is the fourth and tenth most common malignancy in men and women, respectively, and its incidence is increasing annually in the developed countries. Current prognostic parameters cannot predict with certainty the long-term outcome of bladder cancer and as a result there is a need to identify markers that may predict tumor behavior. Furthermore, given the limitations of current therapeutic options (surgery, chemotherapy or immunotherapy and radiotherapy), novel treatment strategies are very much needed. One such strategy targets transcription factors such as nuclear receptors and their upstream activators. Disruption of these transcription factors is a key element in the initiation and maintenance of a malignant phenotype. The nuclear receptor PPARγ is involved in controlling metabolism, cell growth, angiogenesis, and immune and inflammatory responses. In addition, it has also been suggested that it regulates tumor suppression as well as tumor promotion. RXRα is another member of the nuclear receptor superfamily, that partners PPARγ to form the DNA-binding complex. RXR ligands are already being used as chemopreventive agents in various types of cancer. The transcription factor AP-1 is formed by dimerization of Jun and Fos proteins and its activity is often associated with tumor progression. On the other hand, there is also evidence that AP-1 may enhance apoptosis. CBP is one of the most important transcriptional integrators. The competition of PPARγ and AP-1 for CBP is one of the multiple mechanisms that explain the negative PPARγ/AP-1 cross-talk. In the present study, we assessed separate and concurrent expression of the five factors (PPARγ, RXRα, p-c-Jun, c-Fos, CBP) in normal urothelium, precancerous lesions and urothelial carcinomas (UC). Clinical samples were derived from 88 patients who had undergone diagnostic biopsy or therapeutic excision of the bladder, the kidney or the ureter. Parafin section immunohistochemistry was utilized and relative expression was estimated in intracellular compartments, intraepithelial layers and histologic categories of urothelium. All five factors had mainly nuclear pattern of expression. P-c-jun was downregulated in patients older than 70 years old compared to younger ones, whereas age did not affect the expression of the rest four factors. PPARγ, CBP, p-c-Jun and c-Fos were upregulated towards tumorigenesis. PPARγ and CBP showed an inverse relationship with carcinoma level of differentiation. Moreover, PPARγ expression downregulated significantly in invasive tumors compared to non-invasive ones. On the contrary, RXRα expression did not vary significantly along the carcinogenesis course. The following correlations were based on coexpression analysis to reveal molecular interactions between the five factors. The established protective effect of PPARγ on urothelium was accompanied by concomitant RXRα, p-c-Jun and c-Fos moderate or strong expression. In detail, p-c-Jun’s increasing expression strengthened the positive relation of PPARγ with better differentiated, less invasive tumors, whereas c-Fos seemed to mildly lessen PPARγ’s favourable effect in urothelium differentiation. Statistically significant PPARγ upregulation in malignant tissues compared to normal urothelium and in non-invasive tumors compared to invasive ones is suppressed and finally cancelled by CBP’s increasing expression. PPARγ and AP-1 seemed to influence the negative relation of CBP with loss of differentiation and increase of malignant potential in UC, an observation that denotes a cross-talk between these molecular factors. Interestingly, most of the aforementioned correlations were noticed in patients older than 70 years old, but not all of them were plausible in younger patients. The results from the present study could lead to conclusions possibly applicable in chemoprevention and therapy strategies for urothelial carcinomas.

p53, known as the “guardian of the genome”, is the most well-characterized tumor suppressor gene. The central role of p53 is to prevent genome instability. p53 is the central node in an incredibly elaborate genome defense network for receiving various input stress signals and controlling diverse cellular responses. The final output of this network is determined not only by the p53 protein itself, but also by other p53 cooperating proteins. p300 and CBP (CREB-Binding Protein) act as multifunctional regulators of p53 via acetylase and ubiquitin ligase activities. Prior work in vitro has shown that the N-terminal 595 aa of p300 encode both generic ubiquitin ligase (E3) and p53-directed E4 functions. Analysis of p300 or CBP-deficient cells revealed that both coactivators were required for endogenous p53 polyubiquitination and the normally rapid turnover of p53 in unstressed cells. Unexpectedly, p300/CBP ubiquitin ligase activities were absent in nuclear extracts and exclusively cytoplasmic. In the nucleus, CBP and p300 exhibited differential regulation of p53 gene target expression, C-terminal acetylation, and biologic response after DNA damage. p300 activated, and CBP repressed, PUMA expression, correlating with activating acetylation of p53 C-terminal lysines by p300, and a repressive acetylation of p53 lysine-320 induced by CBP. Consistent with their gene expression effects, CBP deficiency augmented, and p300 deficiency blocked, apoptosis after doxorubicin treatment. Subcellular compartmentalization of p300/CBP’s ubiquitination and transcription activities reconciles seemingly opposed functions—cytoplasmic p300/CBP E4 activities ubiquitinate and destabilize p53, while nuclear p300/CBP direct p53 acetylation, target gene activation, and biological outcome after genotoxic stress. p53 is a prominent tumor suppressor gene and it is mutated in more than 50% of human tumors. Reactivation of endogenous p53 is one therapeutic avenue to stop cancer cell growth. In this thesis, we have identified S5as a critical regulator of p53 degradation and activity. S5a is a non-ATPase subunit in the 19S regulatory particle of the 26S proteasome. Our preliminary data indicates that S5a is required for p53 instability and is a negative regulator of p53 tranactivation. As a negative regulator of p53, S5a may therefore also represent a new target for cancer drug development against tumors that specifically maintain wild type p53.